You are here

Activin A antagonist for treatment of cancer-associated cachexia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA203180-01
Agency Tracking Number: R43CA203180
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA14-071
Timeline
Solicitation Year: 2015
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-25
Award End Date (Contract End Date): 2016-03-24
Small Business Information
5448 PIRE AVE
San Diego, CA 92122-4126
United States
DUNS: 068800915
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRADLEY MESSMER
 (858) 455-9976
 messmeb@gmail.com
Business Contact
 BRADLEY MESSMER
Phone: (858) 248-9253
Email: bmessmer@abreosbio.com
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant Cachexia is a major cause of suffering and death among patients with late stage cancers and the current treatment options are limited and ineffective We have identified a novel Activin A inhibitory protein Cryptic that can potentially
eliminate the muscle wasting activity of Activin in cachexia Activin A has been previously validated as a target using other ligand traps such as the Activin receptors ActRIIA and ActRIIB but those molecules are promiscuous in binding to other TGF beta family ligands which leads to compromising side effects Cryptic exhibits a far more targeted activity towards Activins and therefore may be an ideal therapeutic for Activin mediated conditions Preliminary data with an Fc fusion Cryptic Fc has shown in vivo efficacy in an osteoporosis model system with both bone and muscle restorative effects observed The goal of this project is to test Cryptic Fc in a mouse model of cachexia Mice implanted with the C colon adenocarcinoma cell line which rapidly manifest cachexia will be used to evaluate both prevention as well as the reversal of cachexia In specific aim various Cryptic deletion constructs will be prepared and analyzed for Activin binding and pharmacokinetics to identify optimal candidates for development In specific aim qualified Cryptic Fc constructs will be tested in the mouse model If successful these studies will provide proof of concept for Cryptic Fc in the treatment of cachexia and pave the way for more thorough pre clinical development This project is a collaboration between Abreos Biosciences and Dr Martinez Hackert Assistant Professor at Michigan State University and the discoverer of Crypticandapos s Activin inhibiting functions Abreos has secured exclusive rights to develop Cryptic for this and other indications

PUBLIC HEALTH RELEVANCE Cachexia also known as muscle wasting disease is a common and debilitating side effect of many types of cancer This project aims to develop a new treatment that can restore lost muscle for patients suffering from this disease

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government